- Home
- AUUD vs MBIO Comparison
AUUD vs MBIO Comparison
Compare AUUD & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- MBIO
- Stock Information
- Founded
- AUUD 2012
- MBIO 2015
- Country
- AUUD United States
- MBIO United States
- Employees
- AUUD N/A
- MBIO N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AUUD Technology
- MBIO Health Care
- Exchange
- AUUD Nasdaq
- MBIO Nasdaq
- Market Cap
- AUUD 4.2M
- MBIO 4.7M
- IPO Year
- AUUD 2021
- MBIO N/A
- Fundamental
- Price
- AUUD $2.05
- MBIO $1.65
- Analyst Decision
- AUUD
- MBIO
- Analyst Count
- AUUD 0
- MBIO 0
- Target Price
- AUUD N/A
- MBIO N/A
- AVG Volume (30 Days)
- AUUD 2.9M
- MBIO 117.8K
- Earning Date
- AUUD 11-06-2025
- MBIO 11-07-2025
- Dividend Yield
- AUUD N/A
- MBIO N/A
- EPS Growth
- AUUD N/A
- MBIO N/A
- EPS
- AUUD N/A
- MBIO N/A
- Revenue
- AUUD N/A
- MBIO N/A
- Revenue This Year
- AUUD N/A
- MBIO N/A
- Revenue Next Year
- AUUD N/A
- MBIO N/A
- P/E Ratio
- AUUD N/A
- MBIO N/A
- Revenue Growth
- AUUD N/A
- MBIO N/A
- 52 Week Low
- AUUD $1.85
- MBIO $0.89
- 52 Week High
- AUUD $14.60
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- AUUD 38.35
- MBIO 54.22
- Support Level
- AUUD $2.00
- MBIO $1.54
- Resistance Level
- AUUD $2.11
- MBIO $1.68
- Average True Range (ATR)
- AUUD 0.13
- MBIO 0.08
- MACD
- AUUD 0.06
- MBIO 0.03
- Stochastic Oscillator
- AUUD 40.00
- MBIO 92.39
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.